{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,10]],"date-time":"2026-07-10T03:13:06Z","timestamp":1783653186349,"version":"3.55.0"},"reference-count":67,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2022,12,1]],"date-time":"2022-12-01T00:00:00Z","timestamp":1669852800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,12,1]],"date-time":"2022-12-01T00:00:00Z","timestamp":1669852800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,12,1]],"date-time":"2022-12-01T00:00:00Z","timestamp":1669852800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2022,12,1]],"date-time":"2022-12-01T00:00:00Z","timestamp":1669852800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2022,12,1]],"date-time":"2022-12-01T00:00:00Z","timestamp":1669852800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2022,12,1]],"date-time":"2022-12-01T00:00:00Z","timestamp":1669852800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2022,12,1]],"date-time":"2022-12-01T00:00:00Z","timestamp":1669852800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Bioorganic Chemistry"],"published-print":{"date-parts":[[2022,12]]},"DOI":"10.1016\/j.bioorg.2022.106191","type":"journal-article","created":{"date-parts":[[2022,10,6]],"date-time":"2022-10-06T22:27:15Z","timestamp":1665095235000},"page":"106191","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":9,"special_numbering":"C","title":["Structure-based screening and biological validation of the anti-thrombotic drug-dicoumarol as a novel and potent PPAR\u03b3-modulating ligand"],"prefix":"10.1016","volume":"129","author":[{"given":"Lei","family":"Ma","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Junyuan","family":"Tang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guihui","family":"Cai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fangyuan","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qingmei","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhi","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Silin","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiawen","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ning","family":"Hou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei","family":"Yi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.bioorg.2022.106191_b0005","doi-asserted-by":"crossref","first-page":"109119","DOI":"10.1016\/j.diabres.2021.109119","article-title":"IDF Diabetes Atlas: Global, regional and country-level diabetes prevalence estimates for 2021 and projections for 2045","volume":"183","author":"Sun","year":"2022","journal-title":"Diabetes Res. Clin. Pract."},{"issue":"2","key":"10.1016\/j.bioorg.2022.106191_b0010","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1038\/nrendo.2017.151","article-title":"Global aetiology and epidemiology of type 2 diabetes mellitus and its complications","volume":"14","author":"Zheng","year":"2018","journal-title":"Nat. Rev. Endocrinol."},{"issue":"7","key":"10.1016\/j.bioorg.2022.106191_b0015","doi-asserted-by":"crossref","first-page":"1176","DOI":"10.1038\/aps.2018.40","article-title":"Leptin, cardiovascular diseases and type 2 diabetes mellitus","volume":"39","author":"Katsiki","year":"2018","journal-title":"Acta Pharmacol. Sin."},{"key":"10.1016\/j.bioorg.2022.106191_b0020","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1007\/5584_2020_532","article-title":"Non-alcoholic Fatty Liver Disease and Diabetes Mellitus","volume":"1307","author":"Khneizer","year":"2021","journal-title":"Adv. Exp. Med. Biol."},{"issue":"6","key":"10.1016\/j.bioorg.2022.106191_b0025","doi-asserted-by":"crossref","first-page":"364","DOI":"10.1038\/s41574-021-00489-y","article-title":"Novel therapies with precision mechanisms for type 2 diabetes mellitus","volume":"17","author":"Perreault","year":"2021","journal-title":"Nat. Rev. Endocrinol."},{"key":"10.1016\/j.bioorg.2022.106191_b0030","doi-asserted-by":"crossref","first-page":"e2100275","DOI":"10.1002\/advs.202100275","article-title":"Emerging targets in type 2 diabetes and diabetic complications","volume":"8","author":"Demir","year":"2021","journal-title":"Adv. Sci."},{"key":"10.1016\/j.bioorg.2022.106191_b0035","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1016\/j.tips.2004.03.012","article-title":"Peroxisome proliferator-activated receptor gamma in diabetes and metabolism","volume":"25","author":"Rangwala","year":"2004","journal-title":"Trends Pharmacol. Sci."},{"key":"10.1016\/j.bioorg.2022.106191_b0040","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1146\/annurev.biochem.77.061307.091829","article-title":"Fat and beyond: the diverse biology of PPARgamma","volume":"77","author":"Tontonoz","year":"2008","journal-title":"Annu. Rev. Biochem."},{"key":"10.1016\/j.bioorg.2022.106191_b0045","doi-asserted-by":"crossref","first-page":"436","DOI":"10.1016\/j.ejmech.2018.04.061","article-title":"Current anti-diabetic agents and their molecular targets: A review","volume":"152","author":"Kerru","year":"2018","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.bioorg.2022.106191_b0050","doi-asserted-by":"crossref","first-page":"548","DOI":"10.1016\/j.bioorg.2018.02.009","article-title":"Thiazolidinediones as antidiabetic agents: A critical review","volume":"77","author":"Nanjan","year":"2018","journal-title":"Bioorg. Chem."},{"issue":"12","key":"10.1016\/j.bioorg.2022.106191_b0055","doi-asserted-by":"crossref","first-page":"1805","DOI":"10.2165\/00003495-200262120-00007","article-title":"Rosiglitazone: a review of its use in the management of type 2 diabetes mellitus","volume":"62","author":"Wagstaff","year":"2002","journal-title":"Drugs"},{"issue":"11","key":"10.1016\/j.bioorg.2022.106191_b0060","doi-asserted-by":"crossref","first-page":"1792","DOI":"10.1016\/S0149-2918(00)80078-8","article-title":"A systematic review of the clinical effectiveness of pioglitazone in the treatment of type 2 diabetes mellitus","volume":"23","author":"Chilcott","year":"2001","journal-title":"Clin. Ther."},{"issue":"1","key":"10.1016\/j.bioorg.2022.106191_b0065","doi-asserted-by":"crossref","first-page":"256","DOI":"10.2337\/diacare.27.1.256","article-title":"Thiazolidinedione use, fluid retention, and congestive heart failure: a consensus statement from the American Heart Association and American Diabetes Association","volume":"27","author":"Nesto","year":"2004","journal-title":"Diabetes Care"},{"issue":"2","key":"10.1016\/j.bioorg.2022.106191_b0070","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1016\/S1089-3261(03)00020-5","article-title":"Hepatotoxicity of the thiazolidinediones","volume":"7","author":"Tolman","year":"2003","journal-title":"Clin. Liver Dis."},{"issue":"4","key":"10.1016\/j.bioorg.2022.106191_b0075","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1007\/s13300-017-0273-4","article-title":"Pioglitazone and the Risk of Bladder Cancer: A Meta-Analysis","volume":"8","author":"Filipova","year":"2017","journal-title":"Diabetes Ther."},{"issue":"9","key":"10.1016\/j.bioorg.2022.106191_b0080","doi-asserted-by":"crossref","first-page":"2302","DOI":"10.1038\/s41401-022-00858-x","article-title":"Activation of the endocannabinoid system mediates cardiac hypertrophy induced by rosiglitazone","volume":"43","author":"Liu","year":"2022","journal-title":"Acta Pharmacol. Sin."},{"key":"10.1016\/j.bioorg.2022.106191_b0085","doi-asserted-by":"crossref","first-page":"536","DOI":"10.5694\/j.1326-5377.2004.tb06441.x","article-title":"Effectiveness and side effects of thiazolidinediones for type 2 diabetes: real-life experience from a tertiary hospital","volume":"181","author":"Hussein","year":"2004","journal-title":"Med. J. Aust."},{"issue":"4","key":"10.1016\/j.bioorg.2022.106191_b0090","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1517\/13543781003640169","article-title":"Discovery and development of selective PPAR\u03b3 modulators as safe and effective antidiabetic agents","volume":"19","author":"Doshi","year":"2010","journal-title":"Expert Opin. Invest. Drugs"},{"key":"10.1016\/j.bioorg.2022.106191_b0095","doi-asserted-by":"crossref","first-page":"662","DOI":"10.1210\/me.2002-0217","article-title":"Distinct properties and advantages of a novel peroxisome proliferator-activated protein [gamma] selective modulator","volume":"17","author":"Berger","year":"2003","journal-title":"Mol. Endocrinol."},{"key":"10.1016\/j.bioorg.2022.106191_b0100","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1016\/j.ejphar.2015.02.043","article-title":"A step ahead of PPARgamma full agonists to PPARgamma partial agonists: therapeutic perspectives in the management of diabetic insulin resistance","volume":"755","author":"Chigurupati","year":"2015","journal-title":"Eur. J. Pharmacol."},{"issue":"9","key":"10.1016\/j.bioorg.2022.106191_b0105","doi-asserted-by":"crossref","first-page":"4027","DOI":"10.1021\/jm101360s","article-title":"Targeting peroxisome proliferator-activated receptors (PPARs): development of modulators","volume":"55","author":"Pirat","year":"2012","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.bioorg.2022.106191_b0110","doi-asserted-by":"crossref","first-page":"12222","DOI":"10.1038\/srep12222","article-title":"Selective targeting of PPARgamma by the natural product chelerythrine with a unique binding mode and improved antidiabetic potency","volume":"5","author":"Zheng","year":"2015","journal-title":"Sci. Rep."},{"issue":"1","key":"10.1016\/j.bioorg.2022.106191_b0115","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1038\/aps.2014.133","article-title":"A structural perspective on nuclear receptors as targets of environmental compounds","volume":"36","author":"Delfosse","year":"2015","journal-title":"Acta Pharmacol. Sin."},{"issue":"8","key":"10.1016\/j.bioorg.2022.106191_b0120","first-page":"915","article-title":"Peroxisome proliferator-activated receptor structures: Ligand specificity, molecular switch and interactions with regulators","volume":"1771","author":"Zoete","year":"2007","journal-title":"BBA"},{"issue":"14","key":"10.1016\/j.bioorg.2022.106191_b0125","doi-asserted-by":"crossref","first-page":"5381","DOI":"10.1021\/jm501155f","article-title":"Peroxisome proliferator-activated receptor \u03b3 (PPAR\u03b3) and ligand choreography: Newcomers Take the Stage: Miniperspective","volume":"58","author":"Garcia-Vallv\u00e9","year":"2015","journal-title":"J. Med. Chem."},{"issue":"1","key":"10.1016\/j.bioorg.2022.106191_b0130","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1016\/j.str.2011.12.002","article-title":"Couple Dynamics: PPAR\u03b3 and Its Ligand Partners","volume":"20","author":"Yu","year":"2012","journal-title":"Structure."},{"issue":"1","key":"10.1016\/j.bioorg.2022.106191_b0135","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1146\/annurev-physiol-021909-135917","article-title":"Structural overview of the nuclear receptor superfamily: insights into physiology and therapeutics","volume":"72","author":"Huang","year":"2010","journal-title":"Annu. Rev. Physiol."},{"issue":"12","key":"10.1016\/j.bioorg.2022.106191_b0140","doi-asserted-by":"crossref","first-page":"1973","DOI":"10.1002\/cmdc.201000446","article-title":"New Insights on the mechanism of PPAR-targeted drugs","volume":"5","author":"Grether","year":"2010","journal-title":"ChemMedChem"},{"key":"10.1016\/j.bioorg.2022.106191_b0145","doi-asserted-by":"crossref","first-page":"16837","DOI":"10.1038\/s41598-017-17082-x","article-title":"Structures of PPAR\u03b3 complexed with lobeglitazone and pioglitazone reveal key determinants for the recognition of antidiabetic drugs","volume":"7","author":"Lee","year":"2017","journal-title":"Sci. Rep."},{"key":"10.1016\/j.bioorg.2022.106191_b0150","doi-asserted-by":"crossref","first-page":"1285","DOI":"10.3389\/fphar.2020.01285","article-title":"PPARgamma transcription deficiency exacerbates high-fat diet-induced adipocyte hypertrophy and insulin resistance in mice","volume":"11","author":"Guo","year":"2020","journal-title":"Front. Pharmacol."},{"issue":"8","key":"10.1016\/j.bioorg.2022.106191_b0155","doi-asserted-by":"crossref","first-page":"717","DOI":"10.1007\/s10822-011-9446-9","article-title":"Structural insights for the design of new PPARgamma partial agonists with high binding affinity and low transactivation activity","volume":"25","author":"Guasch","year":"2011","journal-title":"J. Comput. Aided Mol. Des."},{"issue":"7305","key":"10.1016\/j.bioorg.2022.106191_b0160","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1038\/nature09291","article-title":"Anti-diabetic drugs inhibit obesity-linked phosphorylation of PPAR\u03b3 by Cdk5","volume":"466","author":"Choi","year":"2010","journal-title":"Nature"},{"issue":"4","key":"10.1016\/j.bioorg.2022.106191_b0165","doi-asserted-by":"crossref","first-page":"815","DOI":"10.1016\/j.cell.2011.09.050","article-title":"Adipocyte NCoR knockout decreases PPAR\u03b3 phosphorylation and enhances PPAR\u03b3 activity and insulin sensitivity","volume":"147","author":"Li","year":"2011","journal-title":"Cell"},{"issue":"3","key":"10.1016\/j.bioorg.2022.106191_b0170","doi-asserted-by":"crossref","first-page":"101030","DOI":"10.1016\/j.jbc.2021.101030","article-title":"The therapeutic potential of inhibiting PPAR\u03b3 phosphorylation to treat type 2 diabetes","volume":"297","author":"Frkic","year":"2021","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.bioorg.2022.106191_b0175","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1007\/s11892-021-01385-5","article-title":"PPAR\u03b3 and Diabetes: Beyond the Genome and Towards Personalized Medicine","volume":"21","author":"Cataldi","year":"2021","journal-title":"Curr. Diab. Rep."},{"key":"10.1016\/j.bioorg.2022.106191_b0180","doi-asserted-by":"crossref","first-page":"3677","DOI":"10.2174\/1381612823666170704125104","article-title":"Peroxisome proliferator-activated receptor gamma (PPAR\u03b3) as a target for concurrent management of diabetes and obesity-related cancer","volume":"23","author":"Wang","year":"2017","journal-title":"Curr. Pharm. Des."},{"issue":"1","key":"10.1016\/j.bioorg.2022.106191_b0185","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1161\/RES.0b013e3182435d88","article-title":"A second chance for a PPAR\u03b3 targeted therapy?","volume":"110","author":"Norris","year":"2012","journal-title":"Circ. Res."},{"key":"10.1016\/j.bioorg.2022.106191_b0190","doi-asserted-by":"crossref","first-page":"1258","DOI":"10.1016\/j.str.2007.07.014","article-title":"Partial agonists activate PPARgamma using a helix 12 independent mechanism","volume":"15","author":"Bruning","year":"2007","journal-title":"Structure"},{"key":"10.1016\/j.bioorg.2022.106191_b0195","doi-asserted-by":"crossref","first-page":"4811","DOI":"10.1021\/acs.jmedchem.0c00048","article-title":"Insights into PPARgamma Phosphorylation and Its Inhibition Mechanism","volume":"63","author":"Montanari","year":"2020","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.bioorg.2022.106191_b0200","doi-asserted-by":"crossref","first-page":"665","DOI":"10.1016\/j.cmet.2020.08.016","article-title":"Obesity-Linked PPARgamma S273 Phosphorylation Promotes Insulin Resistance through Growth Differentiation Factor 3","volume":"32","author":"Hall","year":"2020","journal-title":"Cell Metab."},{"key":"10.1016\/j.bioorg.2022.106191_b0205","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1038\/nm.3159","article-title":"PPARgamma signaling and metabolism: the good, the bad and the future","volume":"19","author":"Ahmadian","year":"2013","journal-title":"Nat. Med."},{"issue":"7365","key":"10.1016\/j.bioorg.2022.106191_b0210","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1038\/nature10383","article-title":"Antidiabetic actions of a non-agonist PPAR\u03b3 ligand blocking Cdk5-mediated phosphorylation","volume":"477","author":"Choi","year":"2011","journal-title":"Nature"},{"key":"10.1016\/j.bioorg.2022.106191_b0215","doi-asserted-by":"crossref","first-page":"26618","DOI":"10.1074\/jbc.M114.566794","article-title":"A novel non-agonist peroxisome proliferator-activated receptor gamma (PPARgamma) ligand UHC1 blocks PPARgamma phosphorylation by cyclin-dependent kinase 5 (CDK5) and improves insulin sensitivity","volume":"289","author":"Choi","year":"2014","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.bioorg.2022.106191_b0220","doi-asserted-by":"crossref","first-page":"28169","DOI":"10.1074\/jbc.M111.332106","article-title":"GQ-16, a novel peroxisome proliferator-activated receptor gamma (PPARgamma) ligand, promotes insulin sensitization without weight gain","volume":"287","author":"Norris","year":"2012","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.bioorg.2022.106191_b0225","doi-asserted-by":"crossref","first-page":"2260","DOI":"10.1039\/C9SC05487A","article-title":"Identification and structural insight of an effective dentification and structural insight of an effective PPAR\u03b3 modulator with improved therapeutic index for anti-diabetic drug discovery","volume":"11","author":"Jiang","year":"2020","journal-title":"Chem. Sci."},{"key":"10.1016\/j.bioorg.2022.106191_b0230","doi-asserted-by":"crossref","first-page":"105860","DOI":"10.1016\/j.phrs.2021.105860","article-title":"Identification of the anti-fungal drug fenticonazole nitrate as a novel PPAR\u03b3-modulating ligand with good therapeutic index: Structure-based screening and biological validation","volume":"173","author":"Ma","year":"2021","journal-title":"Pharmacol. Res."},{"issue":"5","key":"10.1016\/j.bioorg.2022.106191_b0235","doi-asserted-by":"crossref","first-page":"2146","DOI":"10.7150\/ijbs.69116","article-title":"Urolithin A protects against acetaminophen-induced liver injury in mice via sustained activation of Nrf2","volume":"18","author":"Gao","year":"2022","journal-title":"Int. J. Biol. Sci."},{"issue":"1","key":"10.1016\/j.bioorg.2022.106191_b0240","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1074\/jbc.M111.294785","article-title":"Identification and mechanism of 10-carbon fatty acid as modulating ligand of peroxisome proliferator-activated receptors","volume":"287","author":"Malapaka","year":"2012","journal-title":"J. Biol. Chem."},{"issue":"1","key":"10.1016\/j.bioorg.2022.106191_b0245","article-title":"Identification of a novel selective PPAR\u03b3 ligand with a unique binding mode and improved therapeutic profile in vitro","volume":"7","author":"Yi","year":"2017","journal-title":"Sci. Rep."},{"issue":"6698","key":"10.1016\/j.bioorg.2022.106191_b0250","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1038\/25931","article-title":"Ligand binding and co-activator assembly of the peroxisome proliferator-activated receptor-\u03b3","volume":"395","author":"Nolte","year":"1998","journal-title":"Nature"},{"key":"10.1016\/j.bioorg.2022.106191_b0255","doi-asserted-by":"crossref","DOI":"10.1155\/2015\/816856","article-title":"Review of the structural and dynamic mechanisms of PPAR\u03b3 partial agonism","volume":"2015","author":"Kroker","year":"2015","journal-title":"PPAR Res."},{"issue":"1","key":"10.1016\/j.bioorg.2022.106191_b0260","doi-asserted-by":"crossref","DOI":"10.1038\/ncomms4571","article-title":"An alternate binding site for PPAR\u03b3 ligands","volume":"5","author":"Hughes","year":"2014","journal-title":"Nat. Commun."},{"issue":"1","key":"10.1016\/j.bioorg.2022.106191_b0265","doi-asserted-by":"crossref","DOI":"10.1038\/s41467-020-14750-x","article-title":"A molecular switch regulating transcriptional repression and activation of PPAR\u03b3","volume":"11","author":"Shang","year":"2020","journal-title":"Nat. Commun."},{"issue":"22","key":"10.1016\/j.bioorg.2022.106191_b0270","doi-asserted-by":"crossref","first-page":"126664","DOI":"10.1016\/j.bmcl.2019.126664","article-title":"Design, synthesis, and evaluation of potent novel peroxisome proliferator-activated receptor \u03b3 indole partial agonists","volume":"29","author":"Eeda","year":"2019","journal-title":"Bioorg. Med. Chem. Lett."},{"issue":"11","key":"10.1016\/j.bioorg.2022.106191_b0275","doi-asserted-by":"crossref","first-page":"2553","DOI":"10.1111\/dom.13843","article-title":"A novel specific peroxisome proliferator-activated receptor \u03b3 (PPAR\u03b3) modulator YR4-42 ameliorates hyperglycaemia and dyslipidaemia and hepatic steatosis in diet-induced obese mice","volume":"21","author":"Huan","year":"2019","journal-title":"Diabetes Obes. Metab."},{"issue":"21","key":"10.1016\/j.bioorg.2022.106191_b0280","doi-asserted-by":"crossref","first-page":"13124","DOI":"10.1021\/acs.jmedchem.0c01555","article-title":"A Novel N-Substituted Valine Derivative with Unique Peroxisome Proliferator-Activated Receptor \u03b3 Binding Properties and Biological Activities","volume":"63","author":"Peiretti","year":"2020","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.bioorg.2022.106191_b0285","doi-asserted-by":"crossref","first-page":"1018","DOI":"10.1021\/acs.jmedchem.0c01512","article-title":"Tetrazanbigen derivatives as peroxisome proliferator-activated receptor gamma (PPARgamma) partial agonists: design, synthesis, structure-activity relationship, and anticancer activities","volume":"64","author":"Gan","year":"2021","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.bioorg.2022.106191_b0290","doi-asserted-by":"crossref","first-page":"105193","DOI":"10.1016\/j.phrs.2020.105193","article-title":"A pharmacological review of dicoumarol: An old natural anticoagulant agent","volume":"160","author":"Sun","year":"2020","journal-title":"Pharmacol. Res."},{"key":"10.1016\/j.bioorg.2022.106191_b0295","doi-asserted-by":"crossref","first-page":"105424","DOI":"10.1016\/j.ejps.2020.105424","article-title":"An insight into the therapeutic applications of coumarin compounds and their mechanisms of action","volume":"152","author":"Garg","year":"2020","journal-title":"Eur. J. Pharm. Sci."},{"issue":"2","key":"10.1016\/j.bioorg.2022.106191_b0300","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1093\/toxsci\/kfr138","article-title":"Inhibition of renal NQO1 activity by dicoumarol suppresses nitroreduction of aristolochic acid I and attenuates its nephrotoxicity","volume":"122","author":"Chen","year":"2011","journal-title":"Toxicol. Sci."},{"issue":"4","key":"10.1016\/j.bioorg.2022.106191_b0305","doi-asserted-by":"crossref","first-page":"558","DOI":"10.1111\/j.1464-410X.2009.08732.x","article-title":"Dicoumarol enhances doxorubicin-induced cytotoxicity in p53 wild-type urothelial cancer cells through p38 activation","volume":"105","author":"Matsui","year":"2010","journal-title":"BJU Int."},{"issue":"3","key":"10.1016\/j.bioorg.2022.106191_b0310","doi-asserted-by":"crossref","first-page":"522","DOI":"10.1016\/j.jhep.2020.09.019","article-title":"Dicoumarol, an NQO1 inhibitor, blocks cccDNA transcription by promoting degradation of HBx","volume":"74","author":"Cheng","year":"2021","journal-title":"J. Hepatol."},{"issue":"5","key":"10.1016\/j.bioorg.2022.106191_b0315","doi-asserted-by":"crossref","first-page":"1238","DOI":"10.1124\/mol.65.5.1238","article-title":"NAD (P) H: quinone oxidoreductase 1: role as a superoxide scavenger","volume":"65","author":"Siegel","year":"2004","journal-title":"Mol. Pharmacol."},{"issue":"2","key":"10.1016\/j.bioorg.2022.106191_b0320","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1021\/acs.chemrestox.7b00289","article-title":"Reduction and Scavenging of Chemically Reactive Drug Metabolites by NAD(P)H: Quinone Oxidoreductase 1 and NRH: Quinone Oxidoreductase 2 and Variability in Hepatic Concentrations","volume":"31","author":"den Braver-Sewradj","year":"2018","journal-title":"Chem. Res. Toxicol."},{"issue":"4","key":"10.1016\/j.bioorg.2022.106191_b0325","doi-asserted-by":"crossref","first-page":"576","DOI":"10.1021\/tx400431k","article-title":"Human NAD(P)H:quinone oxidoreductase 1 (NQO1)-mediated inactivation of reactive quinoneimine metabolites of diclofenac and mefenamic acid","volume":"27","author":"Vredenburg","year":"2014","journal-title":"Chem. Res. Toxicol."},{"issue":"1-2","key":"10.1016\/j.bioorg.2022.106191_b0330","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1016\/j.mrfmmm.2004.05.023","article-title":"Contribution of NAD(P)H:quinone oxidoreductase 1 to protection against carcinogenesis, and regulation of its gene by the Nrf2 basic-region leucine zipper and the arylhydrocarbon receptor basic helix-loop-helix transcription factors","volume":"555","author":"Nioi","year":"2004","journal-title":"Mutat. Res."},{"issue":"1","key":"10.1016\/j.bioorg.2022.106191_b0335","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1016\/j.pharmthera.2012.12.007","article-title":"Cytochrome P450 enzymes in drug metabolism: regulation of gene expression, enzyme activities, and impact of genetic variation","volume":"138","author":"Zanger","year":"2013","journal-title":"Pharmacol. Ther."}],"container-title":["Bioorganic Chemistry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0045206822005971?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0045206822005971?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,23]],"date-time":"2025-09-23T08:45:03Z","timestamp":1758617103000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0045206822005971"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,12]]},"references-count":67,"alternative-id":["S0045206822005971"],"URL":"https:\/\/doi.org\/10.1016\/j.bioorg.2022.106191","relation":{},"ISSN":["0045-2068"],"issn-type":[{"value":"0045-2068","type":"print"}],"subject":[],"published":{"date-parts":[[2022,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Structure-based screening and biological validation of the anti-thrombotic drug-dicoumarol as a novel and potent PPAR\u03b3-modulating ligand","name":"articletitle","label":"Article Title"},{"value":"Bioorganic Chemistry","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bioorg.2022.106191","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"106191"}}